/NKTX
NKTX Stock - Nkarta, Inc.
Healthcare|BiotechnologyNASDAQ
$2.06-5.28%
$0.12 (-5.28%) • Jan 13
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.73
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1029.8%upside
Target: $23.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NKTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.04 – $2.09
TARGET (TP)$23.33
STOP LOSS$1.90
RISK/REWARD1:128.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.61
52W High$2.74
52W Low$1.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-5,869,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-128,194,000 | $-131,650,000 | $-118,955,000 | $-86,429,000 | $-51,508,000 |
| Net Income | $-108,790,000 | $-117,501,000 | $-113,837,000 | $-86,075,000 | $-91,361,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.60 | $-2.40 | $-2.61 | $-2.62 | $-1.59 |
Company Overview
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
1
17%
Buy / Outperform
5
83%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$21
Average Target
↑ 925.0% Upside
Now
$14
Low
$21
Average
$30
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 15th 2025 | William Blair | Downgrade | Market Perform | - |
| October 9th 2024 | Rodman & Renshaw | Initiation | Buy | $14 |
| August 14th 2024 | Raymond James | Upgrade | Strong Buy | $16 |
| March 22nd 2024 | Raymond James | Downgrade | Outperform | $16← $13 |
| December 22nd 2022 | Oppenheimer | Downgrade | Perform | - |
| October 10th 2022 | Canaccord Genuity | Initiation | Buy | $25 |
| July 28th 2022 | Needham | Initiation | Buy | $26 |
| July 18th 2022 | SVB Leerink | Initiation | Outperform | $30 |
Earnings History & Surprises
NKTXBeat Rate
74%
Last 19 quarters
Avg Surprise
+7.5%
EPS vs Estimate
Beats / Misses
14/5
Last 12 quarters
Latest EPS
$-0.29
Q4 2025
EPS Surprise History
Q1 24
+8.1%
$-0.57vs$-0.62
Q2 24
-3.6%
$-0.58vs$-0.56
Q3 24
+30.6%
$-0.34vs$-0.49
Q4 24
-5.4%
$-0.39vs$-0.37
Q1 25
+14.6%
$-0.35vs$-0.41
Q2 25
+2.3%
$-0.43vs$-0.44
Q3 25
+16.2%
$-0.31vs$-0.37
Q4 25
+9.4%
$-0.29vs$-0.32
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.32 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.32 | $-0.29 | +9.4% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.37 | $-0.31 | +16.2% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.44 | $-0.43 | +2.3% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.37 | $-0.39 | -5.4% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.49 | $-0.34 | +30.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.56 | $-0.58 | -3.6% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.62 | $-0.57 | +8.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.67 | $-0.52 | +22.4% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.69 | $-0.68 | +1.4% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.71 | $-0.63 | +11.3% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.65 | $-0.67 | -3.1% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.62 | $-0.58 | +6.5% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.59 | $-0.48 | +18.6% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.73 | $-0.63 | +13.7% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.75 | $-0.69 | +8.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.71 | $-0.68 | +4.2% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.65 | $-0.66 | -1.5% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.53 | $-0.59 | -11.3% | ✗ MISS |
Latest News
Stifel Maintains Buy on Nkarta, Lowers Price Target to $11
➖ NeutralBenzinga•Nov 11, 2025, 04:03 PM•Also:
Nkarta GAAP EPS of -$0.29 beats by $0.02
➖ NeutralSeeking Alpha•Nov 10, 2025, 09:52 PM
Nkarta Q3 EPS $(0.29) Beats $(0.35) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:47 PM
Nkarta To Present NKX019 Data At ACR Convergence 2025 Showing Immune Reset In Non-Hodgkin Lymphoma And Preclinical Efficacy In Vitro Autoimmune Disease Models
📈 PositiveBenzinga•Oct 22, 2025, 02:14 PM
Nkarta Posts Narrower Loss in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 08:12 PM
Frequently Asked Questions about NKTX
What is NKTX's current stock price?
Nkarta, Inc. (NKTX) is currently trading at $2.06 per share. The stock has moved -5.28% today.
What is the analyst price target for NKTX?
The average analyst price target for NKTX is $23.33, based on 1 analyst.
What sector is Nkarta, Inc. in?
Nkarta, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NKTX's market cap?
Nkarta, Inc. has a market capitalization of $0.15 billion, making it a small-cap company.
Does NKTX pay dividends?
No, Nkarta, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALEC
Alector, Inc.
$1.89
Mkt Cap: $0.2B
APLT
Applied Therapeutics, Inc.
$0.10
Mkt Cap: $0.0B
CYBN
Cybin Inc.
$8.28
Mkt Cap: $0.4B
ELTX
Elicio Therapeutics, Inc.
$7.54
Mkt Cap: $0.1B
FATE
Fate Therapeutics, Inc.
$1.05
Mkt Cap: $0.1B
FBRX
Forte Biosciences, Inc.
$30.80
Mkt Cap: $0.4B
MOLN
Molecular Partners AG
$4.15
Mkt Cap: $0.2B
PEPG
PepGen Inc.
$5.66
Mkt Cap: $0.4B
SAVA
Cassava Sciences, Inc.
$2.06
Mkt Cap: $0.1B
VOR
Vor Biopharma Inc.
$14.09
Mkt Cap: $0.1B
Explore stocks similar to NKTX for comparison